A TCR bispecific pipeline starts to build behind Immunocore’s Kimmtrak

FDA’s approval last week of Immunocore’s Kimmtrak marked a turning point for bispecifics in solid tumors and a first for any TCR bispecific. The success is likely to trigger investment in new TCR bispecific platforms, but for now the modality’s pipeline is limited in target breath and biotech players. 

Unlike traditional bispecific antibodies that combine antibody domains against two distinct cell surface antigens, TCR bispecifics combine a standard antibody domain with one that functions as a T cell receptor. The TCR piece of the bispecific enables it to target peptides that are derived from intracellular targets and bound to MHC molecules on the cell surface. ...